Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia
David G. Cotter, … , Gary J. Patti, Peter A. Crawford
David G. Cotter, … , Gary J. Patti, Peter A. Crawford
Published October 27, 2014
Citation Information: J Clin Invest. 2014;124(12):5175-5190. https://doi.org/10.1172/JCI76388.
View: Text | PDF
Research Article Hepatology

Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia

  • Text
  • PDF
Abstract

Nonalcoholic fatty liver disease (NAFLD) spectrum disorders affect approximately 1 billion individuals worldwide. However, the drivers of progressive steatohepatitis remain incompletely defined. Ketogenesis can dispose of much of the fat that enters the liver, and dysfunction in this pathway could promote the development of NAFLD. Here, we evaluated mice lacking mitochondrial 3-hydroxymethylglutaryl CoA synthase (HMGCS2) to determine the role of ketogenesis in preventing diet-induced steatohepatitis. Antisense oligonucleotide–induced loss of HMGCS2 in chow-fed adult mice caused mild hyperglycemia, increased hepatic gluconeogenesis from pyruvate, and augmented production of hundreds of hepatic metabolites, a suite of which indicated activation of the de novo lipogenesis pathway. High-fat diet feeding of mice with insufficient ketogenesis resulted in extensive hepatocyte injury and inflammation, decreased glycemia, deranged hepatic TCA cycle intermediate concentrations, and impaired hepatic gluconeogenesis due to sequestration of free coenzyme A (CoASH). Supplementation of the CoASH precursors pantothenic acid and cysteine normalized TCA intermediates and gluconeogenesis in the livers of ketogenesis-insufficient animals. Together, these findings indicate that ketogenesis is a critical regulator of hepatic acyl-CoA metabolism, glucose metabolism, and TCA cycle function in the absorptive state and suggest that ketogenesis may modulate fatty liver disease.

Authors

David G. Cotter, Baris Ercal, Xiaojing Huang, Jamison M. Leid, D. André d’Avignon, Mark J. Graham, Dennis J. Dietzen, Elizabeth M. Brunt, Gary J. Patti, Peter A. Crawford

×

Figure 6

Hepatic metabolic reprogramming in ketogenesis-insufficient mice.

Options: View larger image (or click on image) Download as PowerPoint
Hepatic metabolic reprogramming in ketogenesis-insufficient mice.
(A) Qu...
(A) Quantification of 13C enrichment of glucose from [13C]pyruvate and total glucose concentrations (pmol/mg tissue) (B) determined by NMR in liver extracts of standard chow diet–fed ASO-treated mice perfused with the indicated substrates. n = 7–8/group. (C) Relative transcript abundances of key mediators of fatty acid oxidation and gluconeogenesis in livers from standard chow diet–fed ASO-treated mice. n = 8–10/group. Ppara, peroxisome proliferator–activated receptor α; Ppargc1a, peroxisome proliferator–activated receptor γ coactivator 1-α; Acox1, acyl-CoA oxidase; Cpt1a, carnitine palmitoyl transferase 1-α; Acadm, medium-chain acyl-CoA dehydrogenase; Fgf21, fibroblast growth factor 21; Me2, malic enzyme 2; Pck1, phosphoenol pyruvate carboxykinase; G6pc, glucose-6-phosphatase. (D) Quantification of total α-KG (nmol/mg tissue), (E) succinate (pmol/mg tissue), and (F) total glutamate concentrations (nmol/mg tissue) determined by NMR in liver extracts of standard chow diet–fed ASO-treated mice perfused with the indicated substrates. n = 7–8/group. (G) Concentrations of oxidized, reduced, and total nicotinamide adenine dinucleotide (NAD+, NADH, and NADt, respectively; nmol/g tissue) as well as the ratio of NAD+/NADH levels in the livers of standard chow diet–fed ASO-treated mice perfused with lactate and pyruvate or (H) with lactate and pyruvate in the presence of octanoic acid. n = 4–6/group. *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t test or 2-way ANOVA, as appropriate, versus HMGCS2 ASO–treated mice, or as indicated.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts